PL2485751T3 - GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie - Google Patents

GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie

Info

Publication number
PL2485751T3
PL2485751T3 PL10822514T PL10822514T PL2485751T3 PL 2485751 T3 PL2485751 T3 PL 2485751T3 PL 10822514 T PL10822514 T PL 10822514T PL 10822514 T PL10822514 T PL 10822514T PL 2485751 T3 PL2485751 T3 PL 2485751T3
Authority
PL
Poland
Prior art keywords
glyx
refractory depression
treating refractory
treating
depression
Prior art date
Application number
PL10822514T
Other languages
English (en)
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of PL2485751T3 publication Critical patent/PL2485751T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)
PL10822514T 2009-10-05 2010-10-05 GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie PL2485751T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases
EP10822514.5A EP2485751B1 (en) 2009-10-05 2010-10-05 GLYX-13 for use in a method of treating refractory depression

Publications (1)

Publication Number Publication Date
PL2485751T3 true PL2485751T3 (pl) 2014-10-31

Family

ID=43857351

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15171991T PL2985032T3 (pl) 2009-10-05 2010-10-05 Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
PL10822514T PL2485751T3 (pl) 2009-10-05 2010-10-05 GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15171991T PL2985032T3 (pl) 2009-10-05 2010-10-05 Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona

Country Status (12)

Country Link
EP (4) EP2485751B1 (pl)
CY (1) CY1118530T1 (pl)
DK (2) DK2985032T3 (pl)
ES (2) ES2493316T3 (pl)
HR (1) HRP20140784T1 (pl)
HU (1) HUE043807T2 (pl)
PL (2) PL2985032T3 (pl)
PT (2) PT2985032T (pl)
RS (1) RS53513B1 (pl)
SI (1) SI2485751T1 (pl)
SM (1) SMT201400117B (pl)
WO (1) WO2011044089A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2014059326A2 (en) * 2012-10-12 2014-04-17 Northwestern University Methods of identifying compounds for treating depression and other related diseases
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
MX2016007716A (es) * 2013-12-13 2017-03-31 Univ Northwestern Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
KR20170018072A (ko) * 2014-06-23 2017-02-15 노오쓰웨스턴 유니버시티 편두통을 치료 또는 경감시키는 방법
SG11201701134XA (en) * 2014-08-14 2017-03-30 Naurex Inc Methods of treating depression using nmda modulators
CA3002070A1 (en) * 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
WO2017189920A1 (en) * 2016-04-28 2017-11-02 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US20030065138A1 (en) * 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) * 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2005014797A2 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
EP2485751B1 (en) 2014-05-21
SMT201400117B (it) 2014-11-10
EP2485751A4 (en) 2013-03-13
WO2011044089A3 (en) 2012-02-16
EP2485751A2 (en) 2012-08-15
EP2985032B1 (en) 2019-01-02
RS53513B1 (en) 2015-02-27
HUE043807T2 (hu) 2019-09-30
ES2493316T3 (es) 2014-09-11
CY1118530T1 (el) 2017-07-12
DK2985032T3 (en) 2019-04-15
ES2721448T3 (es) 2019-07-31
PT2485751E (pt) 2014-09-01
HRP20140784T1 (hr) 2014-10-10
PL2985032T3 (pl) 2019-07-31
SI2485751T1 (sl) 2014-10-30
WO2011044089A2 (en) 2011-04-14
DK2485751T3 (da) 2014-08-18
EP2985032A1 (en) 2016-02-17
PT2985032T (pt) 2019-04-24
EP2813236A1 (en) 2014-12-17
EP3488856A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
PL2485751T3 (pl) GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
HK1255283A1 (zh) 用於治療流感的化合物和方法
EP2350793A4 (en) ARRANGEMENT FOR A TOUCH SCREEN AND METHOD FOR MANUFACTURING THE SAME
EP2424352A4 (en) METHODS AND COMPOSITION FOR TREATING MATERIAL
EP2375903A4 (en) METHOD FOR TREATING SILENTNESS
GB0900891D0 (en) A unit for and method of treating waste
IL214919A0 (en) Method for therapeutic use
GB0902705D0 (en) Surface treatment process for implant
GB0908506D0 (en) Method and apparatus for drawing polygons
IL217492A0 (en) Treatment method
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
EP2482567A4 (en) METHOD AND APPARATUS FOR STATUS TRANSITION
GB2483792B (en) Waste treatment method
HK1167167A1 (en) Heater-dryer and control method for heater-dryer
PL2440642T3 (pl) Sposób zmniejszania złych zapachów
EP2260237A4 (en) METHOD FOR OPERATING A HIGH FOOD
GB2471907B (en) A method of treating diamond
PL2439289T3 (pl) Sposób i piec do obróbki cieplnej przedmiotów obrabianych
HK1134746A2 (en) Method for treating boiler surface
PL2336380T3 (pl) Sposób i narzędzie do obróbki powierzchni
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
GB0907249D0 (en) New process and new compounds
IL217326A0 (en) Method and device for treating substrates
GB0820165D0 (en) Process for treatment of materials in a vessel
GB2483039B (en) Method for treating hydrocarbons